Hereditary Hemorrhagic Telangiectasia
📧 Sign up to get email alerts when something new happens for Hereditary Hemorrhagic Telangiectasia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-05-28Clinical Trial Update: ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome [Phase 3]
A Phase 3 randomized trial evaluating tranexamic acid for epistaxis in patients with hereditary hemorrhagic telangiectasia (Osler-Rendu).
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: MRA With Feraheme in HHT [Phase 1]
Phase 1 clinical trial evaluating MRA in combination with Feraheme (ferumoxytol) for hereditary hemorrhagic telangiectasia has completed.
-
CLINICAL_TRIALS trial_result · 2018-10-19Clinical Trial Update: North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 2]
Phase 2 clinical trial update for North American study addressing epistaxis in hereditary hemorrhagic telangiectasia (HHT) has completed wit…
-
CLINICAL_TRIALS trial_result · 2018-04-20Clinical Trial Update: Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating office-sclerotherapy for epistaxis in patients with hereditary hemorrhagic telangiectasia; r…
-
CLINICAL_TRIALS trial_result · 2018-04-20Clinical Trial Update: Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber [Phase 2]
Phase 2 clinical trial evaluating octreotide for gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia (Rendu-Osl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-08-29Clinical Trial Update: Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia [Phase 2]
Phase 2 trial evaluating thalidomide for hereditary hemorrhagic telangiectasia has completed, assessing its efficacy in reducing epistaxis.
-
CLINICAL_TRIALS trial_result · 2017-07-06Clinical Trial Update: Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia [Phase 2]
Phase 2 trial evaluating pazopanib for reducing bleeding in hereditary hemorrhagic telangiectasia; the study was terminated with results pos…
-
CLINICAL_TRIALS trial_result · 2015-11-20Clinical Trial Update: Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 2, Phase 3]
Clinical trial update on bevacizumab nasal spray for epistaxis in hereditary hemorrhagic telangiectasia across Phase 2 and Phase 3. The stud…
-
CLINICAL_TRIALS trial_result · 2013-08-12Clinical Trial Update: Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 2]
Phase 2 trial evaluating intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-28Clinical Trial Update: Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia [Phase 2]
Phase 2 study of PEG-Intron in hereditary hemorrhagic telangiectasia was terminated; results were posted in 2013.
-
CLINICAL_TRIALS trial_result · 2011-08-02Clinical Trial Update: Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding [Phase 2]
Phase 2 clinical trial results indicate that thalidomide reduced gastrointestinal bleeding related to arteriovenous malformations in patient…
-
CLINICAL_TRIALS trial_result · 2009-12-15Clinical Trial Update: Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 3]
Phase 3 clinical trial update noting the completion of a study evaluating tranexamic acid for epistaxis in hereditary hemorrhagic telangiect…
-
CLINICAL_TRIALS trial_result · 2006-09-13Clinical Trial Update: Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial [Phase 2]
A Phase 2 double-blind, placebo-controlled trial evaluating anti-estrogen therapy for hereditary hemorrhagic telangiectasia has completed.